Last reviewed · How we verify
Mivacron (MIVACURIUM)
Mivacron (MIVACURIUM) is a nondepolarizing neuromuscular blocker developed by Abbvie, targeting the acetylcholine receptor. It is a small molecule modality, FDA-approved in 1992 for general anesthesia, muscle relaxation, and endotracheal intubation. Mivacron is off-patent, with two generic manufacturers available. Its half-life is approximately 0.83 hours, and it has 0% bioavailability. As a nondepolarizing neuromuscular blocker, Mivacron is used to facilitate endotracheal intubation and provide muscle relaxation during surgery.
At a glance
| Generic name | MIVACURIUM |
|---|---|
| Sponsor | AbbVie |
| Drug class | Nondepolarizing Neuromuscular Blocker |
| Target | Acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1992 |
Approved indications
- General anesthesia
- Muscle relaxation, function
- Skeletal Muscle Relaxation for Endotracheal Intubation
Common side effects
Drug interactions
- neomycin
- netilmicin
- streptomycin
- tobramycin
Key clinical trials
- Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy (NA)
- Evaluation of Effectiveness of Two Different Doses of Mivacurium in Rapid Sequence Intubation (NA)
- Mivacurium 0.2 mg/kg in Young (18 - 40 Years) and Elderly (= 80 Years) Patients
- : A Comparison of Neuromuscular Transmission in the Muscles During General Anesthesia
- Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
- BIS Monitoring of the Depth of Anaesthesia in Children (NA)
- Can we Antagonize Mivacurium With Neostigmine ? (NA)
- Effect of Deep BLock on Intraoperative Surgical Conditions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mivacron CI brief — competitive landscape report
- Mivacron updates RSS · CI watch RSS
- AbbVie portfolio CI